NCT07308015 Clinical Study on the Treatment of Rhinitis Sicca With Sodium Hyaluronate Adjustable Nasal Irrigator
| NCT ID | NCT07308015 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | China-Japan Union Hospital |
| Condition | Rhinitis Sicca |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-06-16 |
| Primary Completion | 2026-06-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 200 participants in total. It began in 2025-06-16 with a primary completion date of 2026-06-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To observe the therapeutic effect of sodium hyaluronate adjustable nasal irrigator on various types of rhinitis sicca and compare it with the therapeutic effect of the commonly used physiological seawater nasal spray in clinical practice.
Eligibility Criteria
Inclusion Criteria: * Symptoms: Dry nose sensation, little and thick nasal discharge, nosebleeds, itchy nasal cavity, and dryness in the nasopharynx. Physical signs: Nasal endoscopy often reveals dry and congested nasal mucosa, which appears grayish-white or dark red, losing its normal luster. There are often dry, thick secretions, scabs or blood scabs on it. The surface of the nasal mucosa is eroded and ulcers occur. The mucosal lesions are most obvious in the anterior part of the nasal cavity. A diagnosis can be made if one or more of the above symptoms and signs are present. Exclusion Criteria: 1. Those with dry rhinitis and chronic inflammation of the lower respiratory tract. 2. Those confirmed by examination to be caused by certain latent lesions in the mouth, nose, throat, esophagu.s, neck or the whole body 3. Those who have used drugs for treating dry rhinitis or other medications within the past 30 days. 4. Pregnant or lactating women. 5. Those who are allergic to this medicine. 6. Those with severe cardiovascular, liver, kidney and hematopoietic system diseases, etc. 7. Mentally ill patients.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07308015 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Rhinitis Sicca. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07308015 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07308015 currently recruiting?
Yes, NCT07308015 is actively recruiting participants. Contact the research team at mengcd@jlu.edu.cn for enrollment information.
Where is the NCT07308015 trial being conducted?
This trial is being conducted at Changchun, China.
Who is sponsoring the NCT07308015 clinical trial?
NCT07308015 is sponsored by China-Japan Union Hospital. The trial plans to enroll 200 participants.